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Abstract
 
Interferon (IFN) regulatory factor (IRF)-2 was originally described as an antagonist of IRF-1–
 
mediated transcriptional regulation of IFN-inducible genes. IRF-1
 
2
 
/
 
2
 
 mice exhibit defective T
helper type 1 (Th1) cell differentiation. We have used experimental leishmaniasis to show that,
 
like IRF-1
 
2
 
/
 
2
 
 mice, IRF-2
 
2
 
/
 
2
 
 mice are susceptible to 
 
Leishmania major
 
 infection due to a de-
fect in Th1 differentiation. Natural killer (NK) cell development is compromised in both IRF-
1
 
2
 
/
 
2
 
 and IRF-2
 
2
 
/
 
2
 
 mice, but the underlying mechanism differs. NK (but not NK
 
1
 
 T) cell
numbers are decreased in IRF-2
 
2
 
/
 
2
 
 mice, and the NK cells that are present are immature in
phenotype. Therefore, like IRF-1, IRF-2 is required for normal generation of Th1 responses
and for NK cell development in vivo.
 
 
 
In this particular circumstance the absence of IRF-2 can-
not be compensated for by the presence of IRF-1 alone.
 
 
 
Mechanistically, IRF-2 may act as a
functional agonist rather than antagonist of IRF-1 for some, but not all, IFN-stimulated regula-
tory element (ISRE)-responsive genes.
 
Key words: interferon regulatory factor • Th1 • natural killer cells • 
 
Leishmania
 
 • interleukin 15
 
Introduction
 
The IFN regulatory factor (IRF)
 
1
 
 family includes IRF-1
 
through IRF-7, IFN-stimulated gene factor 3
 
g
 
 (ISGF3
 
g
 
),
and IFN consensus sequence-binding protein (ICSBP) (1).
Members of the IRF family were originally identified by
their ability to bind DNA sequences common to the pro-
moters of the IFN-
 
a
 
 and -
 
b
 
 genes (2). IRF family mem-
bers also bind to IFN-stimulated regulatory elements
(ISREs) found in promoters of IFN-inducible genes, such
as inducible nitric oxide synthase (iNOS) (3). Studies of
wild-type embryonic cells and fibroblasts (2, 4) have sug-
gested that IRF-1 and IRF-2 compete for binding at the
same DNA locus and can act as mutual antagonists. Al-
though IRF-1 induces expression of IFN-
 
a
 
/
 
b
 
, IRF-2 re-
presses it (4, 5). Similarly, although IRF-1 has antionco-
genic activity, IRF-2 induces tumorigenicity in embryonic
3T3 cells (6). Mutual antagonism is also suggested by the
phenotypes of mice with a targeted disruption of either the
IRF-1 or the IRF-2 gene (7, 8). Type I IFN induction in
response to poly(I):poly(C) is reduced in IRF-1
 
2
 
/
 
2
 
 fibro-
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Abbreviations used in this paper:
 
 APC, allophycocyanin; BM, bone mar-
row; BrdU, bromodeoxyuridine; ICSBP, IFN consensus sequencing
binding protein; IRF, IFN regulatory factor; iNOS, inducible NO syn-
 
thase; ISRE, IFN-stimulated regulatory element; LNC, LN cell; M
 
f
 
,
macrophage(s); NO, nitric oxide; PEC, peritoneal exudate cell; RAG, re-
combination activating gene; RT, reverse transcription; SN, supernatant. 
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blasts, but upregulated in IRF-2
 
2
 
/
 
2
 
 fibroblasts after infec-
tion with Newcastle disease virus (7, 8). However, in con-
trast to its repressive effects on IFN-related genes, IRF-2
activates the transcription of histone genes and the vascular
cell adhesion molecule (VCAM)-1 gene (9, 10). Further-
more, cooperation between IRF-2 and ICSBP is needed to
repress the transcriptional activity of some promoters, such
as those for MHC class I and 2
 
9
 
-5
 
9
 
oligoadenylate syn-
thetase (11–14). Interestingly, nuclear extracts of spleen
cells from ICSBP
 
2
 
/
 
2
 
 mice contain no detectable IRF-2 ac-
tivity (15), implying a role for ICSBP in the posttranscrip-
tional/translational modification of IRF-2.
ISRE consensus binding sites occur in the promoters of
the IL-4 and IL-12 genes (16, 17), genes that are critical for
the differentiation of naive T cells into Th2 or Th1 cells,
respectively (18–20). IRF-1
 
2
 
/
 
2
 
 mice display a defect in
Th1 differentiation, primarily due to reduced IL-12 pro-
duction (21, 22). Deficiency for ICSBP, which can bind to
IRF-1, leads to a similar decrease in IL-12 synthesis and
impaired Th1 cell differentiation (23, 24). It has recently
been reported that IL-12 production is also dysregulated in
IRF-2–deficient macrophages (25). We thus decided to test
the effects on Th differentiation of a null mutation in IRF-2,
the putative repressor of IRF-1 and an alternative partner
of ICSBP.
Murine cutaneous leishmaniasis, induced by subcutane-
ous inoculation of the protozoan parasite 
 
Leishmania major
 
,
is a useful experimental model in which to study Th differ-
entiation. 
 
L
 
.
 
 major
 
 infection is self-healing in resistant mice
(e.g., C57BL/6) because of the expansion of macrophage-
activating Th1 cells, but is lethal in susceptible mice (e.g.,
BALB/c) due to the expansion of macrophage-deactivating
Th2 cells (26). We have used this model to demonstrate
that IRF-2 is required not only for IL-12 production but
also for the development of Th1 cells and NK cells, a dom-
inant IFN-
 
g
 
–secreting and IL-12–inducing cell population.
 
Materials and Methods
 
Mice.
 
Mice were housed in specific pathogen-free facilities
according to the ethical and institutional guidelines of the On-
tario Cancer Institute and the Institut für Klinische Mikrobiologie
und Immunologie, Universität Erlangen. IRF-2
 
2
 
/
 
2
 
, IRF-2
 
1
 
/
 
2
 
,
and IRF-2
 
1
 
/
 
1
 
 littermates (7), backcrossed for seven generations
to C57BL/6 mice, were used in all experiments. Control BALB/c,
C57BL/6, and 129/SvJ mice were purchased from The Jackson
Laboratory.
 
Infection of Mice with L. major and Monitoring of the Disease.
 
Mice (three to four per group) were infected in the right hind
footpad with 2 
 
3
 
 10
 
7
 
 stationary phase promastigotes of 
 
L
 
.
 
 major
 
strain MHOM/IL/81/FEBNI (27) and the increase in footpad
thickness (expressed as a percentage) was calculated, as described
(22). BALB/c mice had to be killed by week 5 due to severe ul-
cerations. Parasite burden was determined by limiting dilution
analysis as described previously (28).
 
 
 
The number of parasites per
organ or per cell number plated was determined for each mouse.
 
Determination of Cytokines by ELISA.
 
At 4 and 7 wk after in-
fection of mice with
 
 L
 
.
 
 major
 
, right popliteal LNs were removed
and single cell suspensions were made. Cells were restimulated in
 
vitro with or without 
 
L
 
.
 
 major
 
 antigens, as described (22). After
48 h, culture supernatants (SNs) were harvested and IL-4 and
IFN-
 
g
 
 levels were determined using ELISA kits (BD PharMin-
gen).
 
Cell Transfer Experiments.
 
Purification of C57BL/6 wild-type
and recombination activating gene (RAG)-1
 
2
 
/
 
2
 
 B cells was per-
formed as described previously (22) using the MACS system
(Miltenyi Biotec). The resulting cell population contained 
 
.
 
90%
B220
 
1
 
 cells and 
 
,
 
0.5% CD4
 
1
 
 and CD8
 
1
 
 T cells.
To obtain purified CD4
 
1
 
 cells, spleens and LNs from groups
of three IRF-2
 
2
 
/
 
2
 
 or IRF-2
 
1
 
/
 
2
 
 mice were pooled and CD4
 
1
 
 T
cells were isolated using MACS (22). The resulting population
consisted of 
 
.
 
90% (in the case of IRF-2
 
2
 
/
 
2
 
) and 
 
.
 
98% (for
IRF-2
 
1
 
/
 
2
 
) CD4
 
1
 
 cells. Contamination with CD8
 
1
 
 cells was
 
,
 
0.2%. RAG-1
 
2
 
/
 
2
 
 mice (three per group) were reconstituted
intraperitoneally with 11 
 
3
 
 10
 
6
 
 B cells with or without 6 
 
3
 
 10
 
6
 
IRF-2
 
2
 
/
 
2
 
 or IRF-2
 
1
 
/
 
2
 
 CD4
 
1
 
 T cells. On the same day, the re-
constituted mice were infected with 
 
L
 
.
 
 major
 
. 6 wk after cell
transfer, mice were killed and cytokine production as well as
splenic parasite burdens were determined.
 
In Vitro Differentiation of CD4
 
1
 
 T Cells.
 
Pooled single cell
suspensions were prepared from spleens, peripheral LNs, or vis-
ceral LNs of IRF-2
 
2
 
/
 
2
 
 or IRF-21/2 mice. CD41CD62L1 T cells
were isolated using anti-CD4–FITC (Dianova), the anti-FITC
multisort kit (Miltenyi Biotec), and anti-CD62L antibodies con-
jugated to magnetic beads (Miltenyi Biotec). The purified cell
preparation contained 91–99% CD41CD62L1 T cells, referred to
as “naive T cells.” For one experiment, CD41CD62L1 T cells
were further purified (.99%) by FACS® sorting on an EPICS
ELITE machine (Coulter). Purified T cells were plated at 106 in 1
ml Click’s medium in 24-well plates previously coated with 5
mg/ml anti-CD3 mAb (29). Th1 differentiation was induced by
the addition of IL-12p70 (1 ng/ml; BD PharMingen) plus anti–
IL-4 (10% SNs of hybridoma 11B11 [30]), whereas Th2 differen-
tiation was induced with IL-4 (10% SNs of X63Ag8-653-mIL-4
cells [31]) plus neutralizing anti–IL-12 antiserum (10 mg/ml; pro-
vided by Dr. M. Gately, Knoll Pharmaceutical Co., North
Mount Olive, NJ). After 96 h, half of the SN was replaced with
fresh medium containing IL-2 (10% SN of X63Ag8-653-mIL-2
cells [31]) and the cells were transferred to wells without anti-
CD3. After an additional 48 h, the cells were harvested, washed,
and plated (105/well) in 200 ml medium in 96-well plates, with
or without anti-CD3. After 24 h, SNs were tested for IL-4 or
IFN-g production as described above.
Quantitative Real Time Reverse Transcription PCR by TaqMan
Analysis. IRF-21/2 and IRF-22/2 mice were infected with L.
major as described above. 10 d later, popliteal LN cells (LNCs)
were prepared and total RNA was purified using the RNeasy kit
(QIAGEN). Primers (from MWG Biotech Eberserg) and probes
(Eurogentec) were as follows. b-actin: 59, TCACCCACACT-
GTCCCCATCTATGA; 39, GATGCCACAGGATTCCAT-
ACCCA; TaqMan probe, ACGCGCTCCCTCATGCCATC-
CTGCGT. IL-12p35: 59, CCACCCTTGCCCTCCTAAAC;
39, GGCAGCTCCCTCTTGTTGTG; TaqMan probe, ACCT-
CAGTTTGGCCAGGGTCATTCCA. IL-12p40: 59, TTCAG-
TGTCCTGCCAGGAGG; 39, CGGGTCTGGTTTGATGAT-
GTC; TaqMan probe, TGTCACCTGCCCACTGCCGAG.
The one tube reverse transcription (RT)-PCR reaction (25 ml
volume) consisted of 200 nM each primer, 100 nM probe, 300
mM dNTPs, 3.5 mM MnCl2, 2 ml RNA, 2.5 U Tth polymerase
(all from PerkinElmer), and 13 PCR buffer (50 mM bicine, 125
mM potassium acetate, 10 mM EDTA, 8% glycerol, pH 8.2). In
the presence of magnesium, Tth polymerase acts as reverse tran-327 Lohoff et al.
scriptase as well as DNA polymerase. Amplification and detection
were done on an ABI 7700 system with the following profile:
2 min at 508C, 30 min at 608C, 5 min at 958C, and 45 cycles of
958C for 15 s and 608C for 1 min. mRNA levels (mean 6 SD of
duplicate samples for all mice per group) were calculated using
the comparative Ct method and normalization to b-actin (32). All
PCR products were confirmed by size and restriction enzyme di-
gestion on agarose gels.
Determination of IL-12p70 in Macrophage SNs. Peritoneal exu-
date macrophages (PEC Mf) were obtained by peritoneal lavage
5 d after intraperitoneal injection of 1.5 ml 4% thioglycollate
(Difco). 2 3 105 PEC Mf/well in 100 ml RPMI containing 10%
heat-inactivated FCS were seeded in flat-bottomed 96-well mi-
crotiter plates and incubated with LPS (Sigma-Aldrich) and/or
murine recombinant IFN-g (R&D Systems) for 18 h. Culture
SNs were assayed for nitrite (NO22), the stable end product of
NO production, and for IL-12p70 protein. Nitrite was deter-
mined colorimetrically by the Griess method (33), and IL-12p70
by ELISA using commercially available antibody pairs (Opti EIA;
BD PharMingen) according to the manufacturer’s instructions.
In Vitro NK Assays. In vitro evaluations of NK-specific cy-
tolytic activity were performed using the NK-sensitive target cell
line YAC-1, as described previously (34).
Flow Cytometric Analyses of NK and NK1 T Populations in Lym-
phoid Compartments. Peripheral blood was obtained from tail
veins of mice. Single cell suspensions of splenocytes were pre-
pared by passing spleens through a 70-mm plastic mesh followed
by density gradient purification of viable mononuclear cells
(Lympholyte M; Cedarlane Labs). Liver mononuclear cells were
prepared as described previously (35). Bone marrow (BM) cells
were flushed from femurs and tibias, and erythrocytes were lysed
with ammonium chloride solution. Nonspecific staining was
blocked with anti-CD16/CD32 mAb (Fc block, 2.4G2). Cells
were subsequently stained with the mAbs anti-NK1.1–PE
(PK136), anti–pan-NK–FITC (DX5), anti-TCR-b–allophyco-
cyanin (APC) (H57-597), anti–IL-2Rb–FITC (TM-b1), anti-
Ly9.1-biotin (30C7), anti-B220–FITC (RA3-6B2), anti-
CD117–APC (c-kit, 2B8), and anti-CD19–biotin (1D3) (all from
BD PharMingen), and for detection of biotinylated antibody,
streptavidin-RED670 (GIBCO BRL). Cells were analyzed by
flow cytometry on a FACSCalibur™ using CELLQuest™ soft-
ware (Becton Dickinson). Viable lymphocyte populations were
gated on the basis of forward and side scatter, and 10,000 gated
cells/sample were analyzed.
BM Transplantation and Reconstitution of NK Cells. 107 BM
cells were transferred intravenously into lethally irradiated mice
(9.0 Gy), and mononuclear cells isolated from the spleen and liver
were analyzed 10–12 wk later. Irradiated mice were maintained
on acidified water and irradiated chow, with antibiotics in their
drinking water for the first 2 wk.
Determination of IL-15 mRNA Expression. Unfractionated
BM from IRF-21/2 or IRF-22/2 mice of 8–10 wk of age was
cultured for 6 h in medium alone, or medium containing LPS (30
mg/ml) plus IFN-g (100 U/ml). Cells were harvested and total
RNA was prepared by the RNeasy method (QIAGEN). For de-
termination of IL-15 mRNA, 10 mg total RNA was analyzed us-
ing the RiboQuant® multiprobe RNase Protection assay (RPA)
system (BD PharMingen) according to the manufacturer’s in-
structions.
In Vitro Culture of BM NK Cells. Unfractionated BM cells
(1.5  3  106) were cultured for 7 d in 24-well plates in RPMI con-
taining 10% FCS plus 50 ng/ml recombinant human IL-15
(R&D Systems). Cells were harvested, counted, and from the fre-
quency of NK1.11TCR-a/b2 cells determined by flow cytome-
try the number of NK cells was calculated.
In Vitro Culture of CD81 T Cells. LN CD81 T cells were
enriched to z80–90% purity by negative selection using anti–pan
B cell and anti-CD4 T cell magnetic beads (Dynabeads; Dynal).
0.5 3 106 enriched CD81 cells were cultured in 0–100 ng/ml of
human IL-15 (R&D Systems) for 48 h, with bromodeoxyuridine
(BrdU) being added for the final 12 h of culture. Cells were har-
vested, surface stained with anti-CD8–APC (H57-597) and anti-
CD44–PE (IM7), and processed for cell cycle analysis using the
BrdU Flow Kit (BD PharMingen) according to the manufac-
turer’s instructions. The percentage of CD44hiCD81 cells in S
phase was quantified by flow cytometry (FACSCalibur™ using
CELLQuest™ software).
Results
Enhanced Susceptibility of IRF-22/2 Mice to L. major Infec-
tion. To determine the role of IRF-2 in protection
against infection with L. major, the course of leishmaniasis
was examined in wild-type C57BL/6 mice and in IRF-21/2
and IRF-22/2 mice of the resistant C57BL/6 background.
Wild-type C57BL/6 mice developed a temporary swelling
of the footpad which healed by week 7, as did IRF-21/2
mice (Fig. 1 A). In contrast, IRF-22/2 mice developed a
progressive increase in footpad thickness and ulcerations
similar to, but not as prominent as, those in susceptible
BALB/c mice (Fig. 1 A) or IRF-12/2 mice (22).
To determine whether the increased footpad swelling in
IRF-22/2 mice reflected a higher systemic parasite load,
parasite numbers in spleens, lesions, and lesion-draining
Figure 1. Leishmaniasis in
IRF-22/2 mice and rescue of
RAG-12/2 mice by IRF-22/2 T
cells. (A) Time-dependent in-
crease in lesion size after L. major
infection in BALB/c, C57BL/6,
IRF-21/2, and IRF-22/2 mice.
Mice were infected with L. major
as described in Materials and
Methods, and the increase in
footpad thickness (%) was calcu-
lated at the indicated time points.
Data are shown as mean 6 SD of
four mice per group, and are
representative of three indepen-
dent experiments. (B) Protection
of RAG-12/2 mice from L. ma-
jor infection by transfer of IRF-
22/2CD41 T cells. RAG-12/2
mice received either no cells, or
were injected intravenously with
B cells from IRF-21/1 mice
without (B), or with (B 1 IRF-
21/2CD4 or B 1 IRF-22/2
CD4) CD41 T cells from IRF-
21/2 or IRF-22/2 mice, respec-
tively. The same day, all mice
were infected with L. major and
lesion sizes were monitored as
described for A above. Data
shown are the mean 6 SD of
three mice per group.328 Lack of IRF-2 Compromises Th1 Responses and NK Cell Development
popliteal LNs of L. major–infected C57BL/6, IRF-21/2,
and IRF-22/2 mice were analyzed at 4 and 7 wk after in-
fection. C57BL/6 and IRF-21/2 mice with healed local le-
sions contained comparably small numbers of parasites
within footpad lesions and LNs at both time points (Table
I). IRF-21/2 spleens contained more parasites than
C57BL/6 spleens at 7 wk, indicating a gene dosage effect.
In contrast, loss of both IRF-2 alleles led to dramatic in-
creases in parasite burden in the footpad, lesion-draining
LNs, and spleens even at 4 wk. 7 wk after infection, IRF-
22/2 spleens contained 106 times more parasites than
C57BL/6 spleens, a burden equal to that observed in L.
major–infected IRF-12/2 mice (22).
Impaired Th1 Response in L. major–infected IRF-22/2
Mice. In BALB/c mice, the fatal course of leishmaniasis is
accompanied by the increased expansion of Th2 cells at the
expense of Th1 cells (26). To study the role of IRF-2 in
Th1 development in vivo, C57BL/6, IRF-21/2, and IRF-
22/2 mice were infected subcutaneously with L. major. 4
wk later, single cell suspensions of lesion-draining popliteal
LNs were restimulated in vitro with L. major antigens and
the culture SNs were tested 48 h later for IL-4 and IFN-g
production. IRF-21/2 (Table II) and C57BL/6 (not
shown) mice exhibited a strong Th1 response to L. major
antigens in that high levels of IFN-g were detected in the
SNs. However, the production of IFN-g by IRF-22/2
LNCs was 30-fold lower than that of IRF-21/2 LNCs, and
IL-4 production was substantially increased. Similar results
were obtained when cytokine production was assayed 7 wk
after infection, and when splenic cells were tested (data not
shown). These results indicate a striking shift of the im-
mune response phenotype from Th1 to Th2 in IRF-22/2
mice.
Normal Capacity for Th1 Differentiation of IRF-22/2CD41
T Cells In Vivo and In Vitro. A bias towards the Th2 phe-
notype in IRF-22/2 mice could be caused either by a pri-
mary T cell defect or by a lack of microenvironmental sig-
nals necessary for Th1 differentiation. To distinguish
between these two possibilities, CD41 T cells from IRF-
21/2 and IRF-22/2 mice were purified and transferred into
IRF-21/1RAG-12/2 mice, which are wild-type with re-
spect to IRF-2 but lack T and B cells. To compensate for
the lack of B cells, B cells from IRF-21/1 mice were
cotransferred into RAG-12/2 mice. The reconstituted
mice were infected with L. major and the course of disease
was monitored by measuring footpad lesions. RAG-12/2
mice without cell transfer or with reconstitution of B cells
alone showed a progressive increase in lesion size (Fig. 1 B)
and high numbers of parasites (Table III). In contrast, mice
reconstituted with CD41 T cells from either IRF-22/2 or
IRF-21/2 mice healed their lesions to an equal extent and
harbored low numbers of parasites. Thus, IRF-22/2CD41
T cells can successfully limit murine leishmaniasis when
placed into a wild-type environment. The capacity of the
transferred IRF-22/2CD41 T cells to secrete cytokines af-
ter in vitro restimulation with L. major antigens was also
determined (Table III). IRF-22/2CD41 T cells produced
slightly lower total amounts of both IL-4 and IFN-g com-
pared with IRF-21/2CD41 T cells. However, the Th1-
indicative IFN-g/IL-4 ratio was even increased compared
with that of IRF-21/2CD41 cells. Thus, in mice bearing
functional IRF-21/1 APCs, the differentiation in vivo of
IRF-22/2CD41 T cells into Th1 cells was essentially nor-
mal. These experiments indicate that the inability of IRF-
Table I. Clearance of Leishmania Is Defective in IRF-2–deficient Mice
Organ
No. of weeks 
after infection C57BL/61/1 IRF-21/2 IRF-22/2
Footpad 4 5.0 3 105 6 2.5 3 105 2.5 3 105 6 1.7 3 105 2.5 3 107 6 1.5 3 107
7 7.8 3 105 6 7.3 3 105 1,600 6 800 4.0 3 106 6 3.5 3 106
LN 4 1,900 6 400 1,200 6 500 1.6 3 104 6 1.1 3 104
7 35 6 13 108 6 64 1.1 3 105 6 0
Spleen 4 1 6 1 10 6 8 1,500 6 1,200
72   6 1 240 6 96 1.5 3 106 6 3.0 3 105
Parasite burden in the infected footpad, popliteal LN draining the infected footpad, or spleen of individual wild-type C57BL/6, IRF-21/2, or IRF-
22/2 mice (four mice per group) 4 and 7 wk after L. major infection. Results are given as the number of parasites in the footpad, LN, and spleen of
the respective mice. Data represent the mean ± SD of all mice in one group and are representative of three separate experiments.
Table II. Amounts of IL-4 and IFN-g (in pg/ml) Secreted In 
Vitro in Response to L. major Antigens
IRF-21/2 IRF-22/2
2LmAg 1LmAg 2LmAg 1LmAg
IL-4 ,10 ,10 ,10 40 6 9
IFN-g 206 6 98 2,790 6 1,438 75 6 11 88 6 19
Amounts of IFN-g and IL-4 secreted in response to L. major antigens
(LmAg) by total popliteal LNCs of individual IRF-21/2 and IRF-22/2
mice taken 4 wk after infection with L. major. Data are shown as mean ±
SD for three mice in each respective group and are representative of
three independent experiments.329 Lohoff et al.
22/2 mice to develop a Th1 response is not a result of a
primary defect in CD41 T cells.
The capacity of CD41 T cells of IRF-22/2 and IRF-21/2
mice to differentiate into Th1 cells was also compared in
vitro. Naive CD41CD62L1 T cells of both genotypes
were cultured either under neutral conditions or in a cy-
tokine milieu favoring the differentiation of either Th1 or
Th2 cells. After resting and restimulation, culture SNs were
tested for the presence of IL-4 or IFN-g. As shown in Ta-
ble IV, both IRF-22/2 and IRF-21/2 CD41 T cells that
were primed so as to promote a Th1 response indeed se-
creted high amounts of IFN-g and no IL-4, confirming
that Th cells of IRF-22/2 mice have no inherent impedi-
ment to Th1 differentiation. In addition, Th2-primed
IRF-22/2 and IRF-21/2 CD41 T cells secreted high
amounts of IL-4 and lower amounts of IFN-g, showing
that a lack of IRF-2 does not preclude IRF-22/2CD41 T
cells from adopting a Th2 phenotype. Interestingly, how-
ever, Th2-primed IRF-21/2CD41 T cells produced sub-
stantially more IFN-g than IRF-22/2CD41 T cells. Such a
difference was even more obvious between IRF-22/2 and
IRF-21/2 CD41 T cells primed under neutral conditions
(anti-CD3 alone). In the absence of a strong stimulus to-
wards either Th1 or Th2 development, IRF-21/2CD41 T
cells (like wild-type CD41 T cells) spontaneously devel-
oped into Th1 cells, although they produced less IFN-g
than cells stimulated in the presence of IL-12. In contrast,
neutrally primed IRF-22/2CD41 T cells failed to develop
into either Th1 or Th2 cells, a finding reproduced in four
independent experiments using FACS®-sorted cells of pu-
rity .99%. The absence of Th1/Th2 cells was not caused
by apoptosis of IRF-22/2CD41 T cells upon restimulation,
because (a) IRF-22/2CD41 T cells proliferated to the same
extent as IRF-21/2CD41 T cells under neutral conditions,
and (b) IRF-22/2CD41 T cells retained the capacity to dif-
ferentiate into IFN-g– or IL-4–producing cells after sec-
Table III. Cytokine Production after In Vivo Transfer of IRF-21/2 and IRF-22/2 CD41 T Cells into RAG-12/2 Mice
Transferred cells
– IRF-21/1 B cells
IRF-21/1 B cells
1IRF-21/2 CD41
IRF-21/1 B cells
1IRF-22/2 CD41
Parasite burden 3.0 3 107 6 2.7 3 107 7.2 3 106 6 3.6 3 106 8.7 3 104 6 1.3 3 104 4.0 3 104 6 1.3 3 104
In vitro stimulus
2LmAg 1LmAg 2LmAg 1LmAg 2LmAg 1LmAg 2LmAg 1LmAg
IFN-g (pg/ml) ,40 ,40 ,40 ,40 80 6 0 3,500 6 70 ,40 2,000 6 0
IL-4 (pg/ml) ,5 ,5 ,5 ,5 55 6 35 375 6 250 ,5 50 6 14
6 wk after the start of the experiment, splenocytes were prepared from L. major–infected RAG-12/2 mice (three mice per group) as described in
Materials and Methods. Parasite burden (expressed as the number of leishmania per spleen) and cytokine production in pooled cells from each group
were determined as described in Materials and Methods. Data are shown as mean ± SD of triplicate determinations.
Table IV. In Vitro Differentiation of CD41 IRF-21/2 and IRF-22/2 T Cells
IRF-21/2 IRF-22/2
IFN-g IL-4 IFN-g IL-4
Secondary stimulus: 2 anti-CD3 2 anti-CD3 2 anti-CD3 2 anti-CD3
Primary stimulus
Anti-CD3 ,0.016 6 ,0.0075 ,0.0075 ,0.016 ,0.016 ,0.0075 ,0.0075
Anti-CD3 1 IL-4 1 anti–IL-12 ,0.016 13 ,0.0075 65 ,0.016 50 ,0.0075 63
Anti-CD3 1 IL-12 1 anti–IL-4 1 1,260 ,0.0075 ,0.0075 ,0.016 600 ,0.0075 ,0.0075
Pooled naive CD41 T cells were purified from spleens and LNs of IRF-22/2 and control IRF-21/2 mice.  The cells were stimulated with immobilized
anti-CD3 and the indicated (primary stimulus) cytokines and antibody for 96 h, then washed and transferred to wells without anti-CD3. After an
additional 48 h, the cells were washed and restimulated in the presence or absence of anti-CD3 (secondary stimulus).  SNs were harvested after 24 h
and analyzed in triplicate for IFN-g and IL-4 production (in ng/ml) by ELISA. In all cases, the SD of these determinations was ,10%. 330 Lack of IRF-2 Compromises Th1 Responses and NK Cell Development
ondary stimulation in the presence of IL-12 or IL-4 (data
not shown). In addition, IRF-22/2 and IRF-21/2 CD41 T
cells expressed equal levels of CD3 (not shown). These data
suggest that, in a C57BL/6 background, naive CD41 T
cells exhibit a natural bias towards the development of a
Th1 response, but that this Th1 bias is absent in IRF-22/2
CD4 T cells.
Reduced IL-12 but Normal NO Production in IRF-22/2
Mice. In IRF-12/2 mice, defective IL-12p70 production
was identified as the likely reason for the bias towards the
Th2 phenotype (21, 22), prompting us to compare IL-12
production by IRF-21/2, IRF-22/2, and IRF-12/2 PEC
Mf stimulated in vitro with LPS and IFN-g. A marked re-
duction in IL-12p70 produced by IRF-22/2 PEC Mf
compared with IRF-21/2 PEC Mf was observed, particu-
larly at limiting concentrations of in vitro stimuli (Fig. 2 A).
However, the defect in IL-12 production was not as pro-
found as that observed in IRF-12/2 PEC Mf, confirming
recently published data (25).
Production of NO is critical for clearance of L. major
(36).  Despite  their reduced IL-12 secretion, stimulated
IRF-22/2 PEC Mf produced amounts of NO greater than
(in the absence of exogenous IFN-g) or equal to (in the
presence of exogenous IFN-g) those produced by IRF-21/2
PEC Mf (Fig. 2 B). IRF-12/2 PEC Mf failed to produce
any NO in response to these stimuli. Flow cytometric anal-
yses demonstrated that PEC Mf from IRF-21/2, IRF-22/2,
and IRF-12/2 mice had identical forward/side scatter char-
acteristics and stained equally for Mac-11 (CD11b/CD18)
and F4/801. Thus, apart from their defect in IL-12 pro-
duction, IRF-22/2 PEC Mf were very similar in gross
phenotype to IRF-21/2 PEC Mf and clearly functional as
assessed by NO release. Therefore, the enhanced suscepti-
bility to L. major in IRF-22/2 mice is not due to reduced
NO secretion. Normal NO production in the absence of
IRF-2 (but not IRF-1) also implies distinct roles for IRF-1
and IRF-2 in the regulation of at least some inducible
genes.
To demonstrate defective IL-12 production in the ab-
sence of IRF-22/2 in vivo, IL-12 production by popliteal
LNCs during L. major infection was quantified. 10 d after
infection, total RNA was purified from popliteal LNCs and
quantitative RT-PCR was performed to detect expression
of the IL-12 p35 and p40 genes (Fig. 2 C). Approximately
equal amounts of p35 and p40 mRNAs could be detected
in LNCs from uninfected IRF-21/2 and IRF-22/2 mice.
In LNCs of L. major–infected mice, the levels of p35
mRNA (the constitutive IL-12 component) were still
comparable but there was a significant reduction in p40
mRNA (the inducible component) in IRF-22/2 LNCs
compared with IRF-21/2 LNCs, likely accounting for the
defective IL-12 production in IRF-22/2 mice in vivo.
Profound Reduction in NK Cell Numbers in IRF-22/2
Mice. Although Th1 cells are the major players in L. major
clearance, NK cells also have an important role (37, 38).
We thus investigated whether, like IRF-12/2 mice, IRF-
22/2 mice exhibit defects in NK cell development and/or
function. To assess total NK function, poly(I):poly(C),
Figure 2. Defective IL-12p70
production but normal NO se-
cretion by IRF-22/2 PEC Mf.
(A) IL-12p70 production by
PEC Mf in response to LPS, with or without increasing concentrations
of IFN-g, as determined by ELISA. (B) NO production by the PEC
Mf in A as assessed by measurement of NO22. Results for A and B are
representative of two experiments each and are depicted as the mean 6
SD of triplicate samples from two mice per group. ND, not detectable.
(C) Expression of IL-12 p35 and p40 genes.  Total mRNA from
popliteal LNCs of IRF-22/2 and IRF-21/2 mice, either infected with
L. major 10 d earlier or uninfected, was prepared from three mice per
group. Quantitative RT-PCR to detect p35 and p40 mRNA was per-
formed (see Materials and Methods). The values obtained for unin-
fected IRF-22/2 mice were arbitrarily set to one, and the data shown
give the number of fold increase in p35 and p40 expression in IRF-21/2
mice relative to these values. Values shown are mean 6 SD for three
mice per group. One experiment representative of two independent
trials is shown.331 Lohoff et al.
which induces type 1 IFN and activates NK cells, was in-
jected intravenously into IRF-22/2 and IRF-21/2 mice. 1 d
later, splenic mononuclear cells were harvested and tested
in vitro for lytic activity against the NK target cell line
YAC-1 (Fig. 3 A). IRF-22/2 splenocytes displayed a large
decrease in NK activity compared with IRF-21/2 spleno-
cytes, indicating an overall deficit in NK function in this
organ. A strong defect in NK cell activity was also noted in
vivo in a tumor rejection model using the NK-sensitive
cell line RMA-S (data not shown).
To establish if this decreased NK activity correlated with
a reduction in NK cell numbers, the proportion of cells
carrying the NK cell marker NK1.1, with or without
TCR-a/b, was determined in several tissue compartments
of IRF-21/1, IRF-21/2, and IRF-22/2 mice. In spleen and
liver (Fig. 3 B), as well as in peripheral blood (data not
shown), the percentage of NK1.11TCR-a/b2 cells was
dramatically decreased in IRF-22/2 mice compared with
IRF-21/2 and IRF-21/1 mice. Strikingly, approximately
equal numbers of NK1.11TCR-a/b1 T (NK11 T) cells
were observed in all three genotypes.
In contrast to the periphery, the proportion of NK1.11
TCR-a/b2 cells in the BM of IRF-22/2 mice was only
slightly reduced compared with IRF-21/2 controls (2.82 6
1.17 vs. 2.01 6 0.95% in IRF-21/2 and IRF-22/2, respec-
tively, mean percentage of viable lymphocytes gated 6 SD
for 11 mice). Thus, the lack of functional NK activity both
in vivo and in vitro correlates well with the profound re-
duction in NK cell numbers in the periphery, but not the
BM, of IRF-22/2 mice.
Altered NK Cell Development in the Absence of IRF-2.
The development of NK cells requires interaction be-
tween NK progenitors and the BM microenvironment
(39). To identify cell populations affected by a lack of IRF-2,
BM cells from IRF-22/2 mice in a C57BL/6 background
were transferred into irradiated, H-2–compatible 129/SvJ
(129J) mice. The expression of Ly9.1, a marker expressed
on lymphocytes of 129J mice but not C57BL/6 mice, al-
lowed us to distinguish between donor-derived lymphoid
cells (Ly9.12) and BM recipient–derived cells (Ly9.11).
In irradiated 129J mice receiving IRF-22/2 BM (IRF-
22/2®129J), the frequency of donor-derived NK cells
(Ly9.12, TCR-a/b2, NK1.11, DX51) was reduced in
the spleen (Fig. 4 A) and liver (data not shown) com-
pared with irradiated wild-type 129J mice which received
IRF-21/2 BM cells (IRF-21/2®129J). In contrast, the fre-
quency of donor-derived NK1 T cells was comparable in
IRF-21/2®129J and IRF-22/2®129J chimeras (0.4 6 0.1
and 0.4 6 0.1% NK1.11TCR-a/b1, respectively; mean 6
SD for seven mice in each group), showing that there was
not a global lack of engraftment of IRF-2–deficient BM
stem cells. To determine if IRF-22/2 mice are able to pro-
vide an appropriate microenvironment for IRF-22/2 NK
progenitors to differentiate into mature NK cells, we per-
formed the reverse transfer of wild-type 129J BM into irra-
diated C57BL/6 IRF-21/2 or IRF-22/2 mice. In this case,
NK cells derived from the donor 129J mice were distin-
guished by expression of Ly9.1, DX5, and the IL-2Rb
chain (NK1.1 is not expressed on lymphoid cells of 129J
origin). Both 129J®IRF-21/2 and 129J®IRF-22/2 BM
chimeras were able to generate donor-derived NK cells
(Ly9.11, TCR-a/b2, IL-2Rb1, DX51) to a similar extent
in both spleen (Fig. 4 B) and liver (data not shown). These
results show that IRF-2 is required for the optimal devel-
opment of NK cell progenitors into mature NK cells, but is
not required for the maintenance of a BM microenviron-
ment permissive for NK cell development.
The progress of NK cell development can be assessed by
monitoring the expression of the hematopoietic markers
B220 (CD45) and c-kit (CD117). As shown in Fig. 4 C, a
greater proportion of IRF-22/2 BM NK cells had the less
mature NK1.11c-kit1CD192B2201 phenotype than in
IRF-21/2 BM. Percentages of B2201NK1.11TCR-a/
b2CD192 cells were 45.6 6 1.3 (3), 44.5 6 8.7 (9), and
72.0 6 6.5 (9) in IRF-21/1, IRF-21/2, and IRF-22/2
mice, respectively (mean percent 6 SD, number of mice
analyzed in parentheses). Percentages of c-kit1NK1.11
CD192 cells were 16.7 6 2.0 (3), 22.9 6 3.0 (4), and 69.9 6
Figure 3. Defective NK activ-
ity and development in IRF-22/2
mice. (A) In vitro cytolytic ac-
tivity against YAC-1 cells. NK
activity was induced in mice by
injection of poly(I):poly(C), and
lytic activity of splenic NK cells
from IRF-21/2 (d) or IRF-22/2
(s) mice was assessed. Data are
shown as mean 6 SEM for four
mice of each genotype. (B) Fre-
quency of NK cells in lymphoid
compartments of IRF-22/2
mice. SPL, spleen; LIV, liver.
Numbers shown are the mean
percent  6  SEM of NK
(NK1.11TCR-a/b2, top left)
and NK1T (NK1.11TCR-a/
b1, top right) cells for four mice (1/1, 1/2) or six mice (2/2) of 8–12 wk of age. Percentages of TCR-a/b1NK1.12 cells in IRF-21/1, IRF-21/2,
and IRF-22/2 mice were approximately equal in both lymphoid compartments (data not shown).332 Lack of IRF-2 Compromises Th1 Responses and NK Cell Development
6.1 (5) in IRF-21/1, IRF-21/2, and IRF-22/2 mice, re-
spectively (mean percent 6 SD). The surface expression of
these markers reconfirms our observation that NK cell de-
velopment is retarded in IRF-22/2 mice.
Failure of IL-15 to Support NK Development in IRF-22/2
BM. The pivotal role of IL-15 in the differentiation, sur-
vival, and activation of NK cells (for a review, see reference
40), and the defect in IL-15 production observed in IRF-
12/2 mice (41, 42), prompted us to examine IL-15 expres-
sion in IRF-22/2 mice. Expression of IL-15 mRNA spe-
cies was compared in total BM isolated from IRF-21/2 and
IRF-22/2 mice. IL-15 mRNA was found to be present in
greater abundance in IRF-22/2 BM stimulated with LPS
plus IFN-g than in stimulated IRF-21/2 BM (Fig. 5 A). In
conjunction with our BM chimera results, these data indi-
cate that IRF-22/2 BM is indeed capable of producing
physiologically relevant amounts of IL-15.
We next investigated the ability of IL-15 to support
IRF-22/2 NK cell differentiation and proliferation in vitro.
Culture of IRF-21/2 BM in IL-15 for 7 d resulted in the
generation of relatively pure NK cells (z90% NK1.11
TCR-a/b2, data not shown). After 7 d culture in IL-15,
IRF-22/2 BM was also able to generate NK cells (z90%
NK1.11TCR-a/b2, data not shown) but the yield was
markedly reduced compared with IRF-21/2 BM (Fig. 5
B). In a control experiment (not shown), IL-15 was able to
rescue NK cell development in IRF-12/2 BM, confirming
previous reports (41, 42). From this data it can be con-
cluded that IRF-1 is clearly not able to fully compensate
for a lack of IRF-2 in IL-15–induced NK differentiation,
suggesting that the defect in NK development in IRF-22/2
mice differs significantly from that of IRF-12/2 mice.
Surface expression of the IL-2Rb chain is thought to be
essential for the maturation of NK cell progenitors, confer-
ring responsiveness to IL-15 with the subsequent acquisi-
tion of proliferative and lytic potential (43). Both IRF-22/2
and IRF-21/2 BM NK cells displayed equivalent surface
expression of IL-2Rb (data not shown), ruling out a defect
in IL-2Rb expression as the cause of the failure of IL-15 to
induce IRF-22/2 BM NK proliferation. In addition, gc
subunit expression was equivalent in IRF-21/2 and IRF-
22/2 BM NK cells (data not shown). Is the defective IL-15
Figure 4. Lack of IRF-2 results in altered NK cell development but a normal BM mi-
croenvironment. BM was transferred into lethally irradiated hosts, and splenic NK cell re-
constitution was assessed at 10–12 wk after transfer. (A) Transfer of C57BL/6 (Ly9.12)
IRF-21/2 or IRF-22/2 BM into wild-type 129J (Ly9.11) recipients. A representative
FACS® profile is shown, together with the percentage of TCR-a/b2-gated splenic lym-
phocytes identified as NK cells of donor origin (Ly 9.12NK1.11DX51) (mean percent 6
SD, seven mice per group). (B) Transfer of wild-type 129J BM into IRF-21/2 or IRF-
22/2 recipients. A representative FACS® profile and the percentage of TCR-a/b2-gated
splenic lymphocytes identified as NK cells of donor origin (Ly 9.11IL-2Rb1DX51) is shown (mean percent 6 SD, four mice per group). (C) B220 and
c-kit expression on IRF-22/2 BM NK cells reveals an immature phenotype. Histograms show B220 (left) and c-kit (right) expression on BM NK1.11
TCR-a/b2CD192 (B220) and NK1.11CD192 (c-kit) cells. The solid histogram represents an isotype control, the thin line represents IRF-21/2, and the
bold line represents IRF-22/2 cells. Histograms show staining for one mouse in each group, representative of nine (B220) and four to five (c-kit) mice.
Figure 5. IL-15 transcripts can be induced in the absence of IRF-2,
but IRF-22/2 BM NK cells are refractory to the proliferative effects of
IL-15. (A) Expression of IL-15 mRNA by IRF-21/2 and IRF-22/2 BM
stimulated with LPS plus IFN-g as assessed by RNase Protection assay
(top). A shorter exposure of the gel shows the expression of the house-
keeping genes L32 and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (bottom). RNA obtained from BM of two mice of each geno-
type is shown. No IL-15 mRNA was detected in unstimulated BM of ei-
ther genotype (data not shown). (B) Defect in IL-15–mediated NK de-
velopment. BM was cultured in the absence (left) or presence (right) of
IL-15 for 7 d, after which cells were harvested, counted, and analyzed by
flow cytometry. The number of NK1.11TCR-a/b2 cells recovered is
shown. Values are the mean 6 SD for two mice per group. One result
representative of five experiments is shown.333 Lohoff et al.
response seen in NK cells restricted only to that cell type?
To address this question, we cultured enriched CD81 T
cells in various doses of human recombinant IL-15, and as-
sessed proliferation of CD81CD44hi T cells by BrdU in-
corporation using flow cytometry (data not shown). BrdU
incorporation was comparable in both IRF-21/2 and IRF-
22/2 CD81 T cells, indicating that no global defect in IL-
15 responsiveness exists in IRF-2–deficient mice.
The defect in NK cell differentiation therefore has dif-
ferent underlying causes in IRF-1– and IRF-2–deficient
mice, suggesting that IRF-1 is not able to compensate for a
lack or IRF-2 in this respect.
Discussion
In this study, we present novel data showing that the
transcriptional factor IRF-2 is required for Th1 responses
and NK cell development. IRF-22/2 mice failed to mount
a strong Th1 response to L. major infection, and developed
enlarged local skin lesions and highly elevated parasite loads.
In contrast to IRF-12/2 mice, which also show increased
susceptibility to leishmaniasis (22), IRF-22/2 mice pro-
duced normal levels of NO (44), illustrating that the in-
creased susceptibility of IRF-22/2 mice cannot be ex-
plained simply by a defect in iNOS induction. Rather,
IRF-22/2 mice are highly susceptible to L. major infection
because of a skewing of their T cell responses towards a
Th2 phenotype. A similar bias has been demonstrated in
BALB/c mice, the susceptible mouse strain used as the stan-
dard for studies in murine experimental leishmaniasis (25).
The Th2 phenotype of IRF-22/2 mice does not reside
in a primary defect in the ability of CD41 T cells to differ-
entiate into Th1 cells. Transfer of purified IRF-22/2CD41
T cells into susceptible RAG-12/2 mice was as effective as
transfer of IRF-21/2CD41 T cells in protecting the recipi-
ents against leishmaniasis, and IRF-22/2CD41 T cells were
fully able to differentiate into Th1 cells in the IRF-2 com-
petent environment of a RAG-12/2 mouse. IRF-22/2
CD41 T cells were also capable of differentiating into ei-
ther Th1 or Th2 cells in vitro when cocultured with IL-12
or IL-4, respectively. These data clearly show that, under
the appropriate conditions, IRF-22/2CD41 T cells are
perfectly able to differentiate into Th1 cells and that the de-
fect underlying the Th2 bias of IRF-22/2 mice must en-
compass cells other than CD41 T cells.
In fact, our results suggest that defects in several cell
types cooperate to create the Th2 phenotype in IRF-22/2
mice. IRF-22/2 macrophages produce reduced amounts of
IL-12 after in vitro stimulation (25; and this study), and IL-
12p40 mRNA is significantly reduced in the lesion-drain-
ing LNs of IRF-22/2 mice. In vivo, macrophages do not
produce IL-12 constitutively, but are induced to do so by
IFN-g (45). IFN-g is a major product of NK cells, and
IRF-22/2 mice contain drastically reduced numbers of NK
cells. Thus, the defective induction of IL-12 in the absence
of early IFN-g production by NK cells may synergize with
the reduced inherent capacity of IRF-22/2 macrophages to
produce IL-12 to influence Th1 development. In part,
IRF-22/2CD41 T cells by themselves may also contribute
to the Th2 bias, as indicated by their failure to differentiate
in vitro into Th1 cells after anti-CD3 stimulation in the ab-
sence of cytokines. Therefore, it is possible that IRF-2 may
play a role in a recently described pathway of IL-12–inde-
pendent Th1 differentiation (46).
A central role for IL-15 in NK cell progenitor differenti-
ation and proliferation has been clearly demonstrated in
studies of gene-targeted mice lacking components of the
IL-15 receptor (47, 48) or IL-15 itself (49). The lack of NK
cells in IRF-12/2 mice has been attributed to a defect in
IL-15 production in BM (41, 42). In IRF-22/2 mice, IL-
15 transcripts are readily detectable in stimulated IRF-22/2
BM cells and an NK-permissive microenvironment is
present because irradiated IRF-22/2 BM chimeras can sup-
port wild-type NK cell development. However, IRF-22/2
BM NK cells are immature and show reduced proliferation
in response to exogenous IL-15. In contrast to the situation
seen in NK cells, IL-15–induced proliferation of CD44hi
CD81 T cells in vitro is comparable in both IRF-21/2 and
IRF-22/2 cells, indicating that there is no global defect in
IL-15 responsiveness in IRF-2–deficient mice. The precise
molecular defect underlying the reduced responsiveness of
IRF-22/2 NK progenitors to IL-15 and the developmental
retardation of NK cell development is currently under in-
vestigation.
In contrast to the NK cell defect, normal numbers of
NK1 T cells were present in all IRF-22/2 lymphoid com-
partments tested. NK1 T cells constitute an interesting IL-4–
and IFN-g–producing subset of T lymphocytes that exhib-
its a highly skewed TCR repertoire (50). The physiological
role of NK1 T cells remains obscure, but may involve the
production of IL-4 that occurs immediately after CD3
stimulation (51). Because NK1 T cells are present in nor-
mal numbers in IRF-22/2 mice, there may be a relative
overabundance of IL-4 (produced by NK1 T cells) com-
pared with IL-12 (produced by NK cell–dependent mac-
rophages) that also biases towards Th2 responses.
We have shown that IRF-22/2 mice are remarkably
similar to IRF-12/2 mice (21, 22) in terms of their suscep-
tibility to Leishmania infection, their bias towards a Th2 re-
sponse, and their cytokine secretion profiles. Furthermore,
the macrophages of both IRF-12/2 and IRF-22/2 mice
have a diminished capacity to produce IL-12. These results
suggest that IRF-2, like IRF-1, mediates at least part of its
effects through direct transcriptional activation, possibly via
the formation of a complex with another IRF family mem-
ber.  Candidate molecules are IRF-1 itself and ICSBP,
which is expressed in cells of the myeloid and lymphoid
lineages and which has been shown to interact with IRF-1
(13) and IRF-2 (15). This hypothesis would be favored by
the fact that, like IRF-12/2 and IRF-22/2 mice, ICSBP2/2
mice display defective Th1 differentiation (24, 25). How-
ever, the phenotypes of IRF-12/2 and IRF-22/2 mice dif-
fer in three important ways which may at the same time be
evidence for in vivo antagonism of IRF-1 by IRF-2, at
least for some genes. First, IRF-22/2 mice contain normal
numbers of NK1 T cells, whereas these cells are severely334 Lack of IRF-2 Compromises Th1 Responses and NK Cell Development
reduced in IRF-12/2 mice (42). Second, IL-15 expression
is enhanced in BM of IRF-22/2 mice, but absent in IRF-
12/2 BM. Third, NO synthesis in IRF-12/2 macrophages
is almost absent (3) but is normal (44) in IRF-22/2 mac-
rophages. In conclusion, IRF-2 appears to act as an func-
tional agonist rather than antagonist of IRF-1 in the reg-
ulation of some, but not all, genes involved in the
differentiation of Th cells. In addition, IRF-2 is required
for optimal maturation of NK cells.
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